^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
darleukin (L19IL2)
i
Other names: L19IL2, L19-IL2 fusion protein, anti-EDB-interleukin-2 antibody conjugate, L19-IL-2, L19-IL2, anti-EDB-IL2 antibody conjugate
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Philogen
Drug class:
IL-2 stimulant, Fibronectin 1 inhibitor
Related drugs:
17d
PH-ICKPD1-02/21: A phase 2 study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 Pembrolizumab, in stage III/IV unresectable melanoma patients with resistance to anti-PD1 checkpoint inhibitors (INTACT / MeRCI) (2024-519326-20-00)
P1/2, N=65, Not yet recruiting, Philogen S.p.A.
New P1/2 trial • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
17d
PH-L19IL2CORK-01/25: A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors. (2025-522243-17-00)
P1, N=96, Not yet recruiting, Philogen S.p.A.
New P1 trial
|
Jakafi (ruxolitinib) • darleukin (L19IL2)
17d
L19IL2/TNF in patients with basal cell carcinoma (2025-523230-77-00)
P1/2, N=53, Not yet recruiting, Philogen S.p.A.
New P1/2 trial
|
Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
17d
L19IL2/L19TNF in patients with cutaneous squamous cell carcinoma (2025-523231-19-00)
P1/2, N=54, Not yet recruiting, Philogen S.p.A.
New P1/2 trial
|
Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
17d
PHL19IL2TNFCOMB04/24: L19IL2 or L19TNF or L19IL2/TNF in patients with basal cell carcinoma (BCC) (2025-523229-16-00)
P1/2, N=85, Not yet recruiting, Philogen S.p.A.
New P1/2 trial
|
Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
2ms
Theratri: A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors (clinicaltrials.gov)
P1, N=56, Recruiting, Philogen S.p.A. | Not yet recruiting --> Recruiting
Enrollment open
|
FAP (Fibroblast activation protein, alpha)
|
darleukin (L19IL2)
4ms
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=92, Not yet recruiting, Philogen S.p.A.
New P2 trial
|
Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
4ms
L19IL2/TNF in Patients With Basal Cell Carcinoma (clinicaltrials.gov)
P2, N=92, Not yet recruiting, Philogen S.p.A.
New P2 trial
|
Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
4ms
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) (clinicaltrials.gov)
P2, N=180, Not yet recruiting, Philogen S.p.A.
New P2 trial
|
Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
1year
IMMUNOSABR2: IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study (clinicaltrials.gov)
P2, N=88, Terminated, Maastricht University Medical Center | Active, not recruiting --> Terminated; This trial is not transitioning to the Clinical Trial Regulation (CTR) EU No 536/2014.
Trial termination
|
IL2 (Interleukin 2)
|
darleukin (L19IL2)
1year
Theratri: A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination with L19-IL2 As a Treatment of Metastatic FAP-positive Solid Tumors (clinicaltrials.gov)
P1, N=56, Not yet recruiting, Philogen S.p.A. | Initiation date: Dec 2024 --> May 2025
Trial initiation date
|
darleukin (L19IL2)
over1year
Theratri: A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination with L19-IL2 As a Treatment of Metastatic FAP-positive Solid Tumors (clinicaltrials.gov)
P1, N=56, Not yet recruiting, Philogen S.p.A.
New P1 trial • Combination therapy • Metastases
|
darleukin (L19IL2)
Share via
